SecurityCTSO / Cytosorbents Corp (23283X206)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding31,459,443 shares (as of 2018-06-30)
Total Insiders11
Total Directors6
Total Officers5

Stock Insider Trading (from SEC Form 4)

Cytosorbents Corp insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CTSO / Cytosorbents Corp insiders include Mortensen Eric R. BATOR MICHAEL G., Sobel Alan D., Chan Phillip P., BARTLETT ROBERT HAWES, Capponi Vincent, Jones Edward Raymond, Gunton James T., NJTC INVESTMENT FUND, LP, and BLOCH KATHLEEN P., Kraus Al, .

Insider Roster

Insider Dir Off 10% Shares Owned
BLOCH KATHLEEN P. Chief Financial Officer
X 259,004
Capponi Vincent Chief Operating Officer
X 332,768
Chan Phillip P. President and CEO, Director
X X 461,281
Sobel Alan D. Director
X 69,300
BATOR MICHAEL G. Director
X 73,800
Jones Edward Raymond Director
X 71,800
Kraus Al Director
X 125,046
Mortensen Eric R. Chief Medical Officer
X 36,500
BARTLETT ROBERT HAWES Chief Medical Officer
X
NJTC INVESTMENT FUND, LP 10% Owner
X
Gunton James T. Director, 10% Owner
X X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-03 4 BLOCH KATHLEEN P. S X D 12.151 -3,600 259,004 3,147,158
2018-08-03 4 BLOCH KATHLEEN P. S X D 12.75 -6,200 262,604 3,348,201
2018-08-03 4 BLOCH KATHLEEN P. S X D 12.85 -200 268,804 3,454,131
2018-08-03 4 BLOCH KATHLEEN P. M X D 2.875 10,000 269,004
2018-08-03 4 Capponi Vincent S X D 13.08 -7,600 332,768 4,352,605
2018-08-03 4 Capponi Vincent M X D 3.45 7,600 340,368
2018-08-02 4 Capponi Vincent S X D 13.00 -2,835 332,768 4,325,984
2018-08-02 4 Capponi Vincent M X D 3.45 2,835 335,603
2018-06-15 4 Capponi Vincent F D 12.35 -15,215 332,768
2018-06-15 4 Capponi Vincent S X D 12.00 -8,633 347,983 4,175,796
2018-06-15 4 Capponi Vincent M D 0.875 40,000 367,983
2018-06-15 4 Capponi Vincent M X D 3.75 8,633 327,983
2018-06-14 4 Capponi Vincent S X D 12.00 -11,367 356,616 4,279,392
2018-06-14 4 Capponi Vincent M X D 3.75 11,367 319,350
2018-06-11 4 Chan Phillip P. X D 3.75 8,000 461,281
2018-05-16 4 Capponi Vincent S X D 9.00 -4,846 317,551 2,857,959
2018-05-16 4 Capponi Vincent M X D 0.875 4,846 322,397
2018-05-17 4 Capponi Vincent S X D 10.00 -20,000 317,551 3,175,510
2018-05-17 4 Capponi Vincent S X D 10.00 -8,000 337,551 3,375,510
2018-05-17 4 Capponi Vincent M X D 0.875 20,000 345,551
2018-05-17 4 Capponi Vincent M X D 4.20 8,000 325,551
2018-05-15 4 Capponi Vincent S X D 9.00 -3,154 317,551 2,857,959
2018-05-15 4 Capponi Vincent S X D 9.00 -4,000 320,705 2,886,345
2018-05-15 4 Capponi Vincent M X D 0.875 3,154 324,705
2018-05-15 4 Capponi Vincent M X D 4.20 4,000 321,551
2018-05-15 4 BLOCH KATHLEEN P. S X D 8.75 -12,400 262,304 2,295,160
2018-05-15 4 BLOCH KATHLEEN P. M X D 4.69 12,400 274,704
2018-05-16 4 BLOCH KATHLEEN P. S X D 9.00 -12,400 262,304 2,360,736
2018-05-16 4 BLOCH KATHLEEN P. M X D 4.69 12,400 274,704
2018-05-14 4 BLOCH KATHLEEN P. S X D 8.50 -10,000 262,304 2,229,584
2018-05-14 4 BLOCH KATHLEEN P. M X D 2.90 10,000 272,304
2018-03-15 4 Kraus Al A D 3,300 125,046
2018-03-15 4 Jones Edward Raymond A D 3,300 71,800
2018-03-15 4 BATOR MICHAEL G. A D 3,300 73,800
2018-03-15 4 Sobel Alan D. A D 3,300 69,300
2018-04-17 4 BLOCH KATHLEEN P. S X D 8.25 -120 262,304 2,164,008
2018-04-17 4 BLOCH KATHLEEN P. M X D 4.69 120 262,424
2018-02-21 4 BLOCH KATHLEEN P. S X D 8.00 -10,000 267,870 2,142,960
2018-02-21 4 BLOCH KATHLEEN P. M X D 2.90 10,000 277,870
2018-03-15 4 Mortensen Eric R. A D 20,000 36,500
2018-03-15 4 BLOCH KATHLEEN P. A D 8,800 266,870
2018-03-15 4 Chan Phillip P. A D 10,300 440,713
2018-03-15 4 Capponi Vincent A D 10,100 317,551
2018-03-15 4 BLOCH KATHLEEN P. S X D 8.25 -11,176 259,070 2,137,328
2018-03-15 4 BLOCH KATHLEEN P. M X D 4.69 11,176 270,246
2018-03-13 4 BLOCH KATHLEEN P. S X D 8.25 -1,104 259,070 2,137,328
2018-03-13 4 BLOCH KATHLEEN P. M X D 4.69 1,104 260,174
2018-02-28 4 Mortensen Eric R. A D 14,000 16,500
2018-02-28 4 Chan Phillip P. A D 43,000 430,413
2018-02-28 4 BLOCH KATHLEEN P. A D 34,700 259,070
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Revisiting Cytosorbents

2018-08-12 seekingalpha
The stock of this name has almost tripled in the past year as investors have bid up this 'razor & razor blade' story. (1-0)

Cytosorbents' (CTSO) CEO Phillip Chan on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good afternoon, and welcome to the Cytosorbents Second Quarter 2018 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that the call will be recorded at the company’s request. (1-2)

Cytosorbents' (CTSO) CEO Phillip Chan on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good afternoon and welcome to the Cytosorbents' First Quarter 2018 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request.